Positions

Overview

  • Dr. Garvey is Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham. He obtained his MD degree, cum laude, from St. Louis University in 1978, and completed residency training in Internal Medicine at Barnes Hospital, Washington University, in 1981. He then was a clinical fellow in Endocrinology and Metabolism at the University of Colorado Health Sciences Center and University of California, San Diego School of Medicine. He subsequently held faculty posts at the University of California, School of Medicine (Assistant Professor), Indiana University School of Medicine (Associate and full Professor), and from 1994 to 2003 was the Director of the Division of Endocrinology, Diabetes, and Medical Genetics at the Medical University of South Carolina. Dr. Garvey moved to UAB on June 1, 2004.

    Dr. Garvey has achieved international recognition for his research in the metabolic, molecular, and genetic pathogenesis of insulin resistance, Type 2 Diabetes, and obesity. His studies have involved the cellular and molecular biology of cell and animal models, metabolic investigations of human subjects on metabolic research wards, and the genetic basis of diseases in Gullah-speaking African Americans, Pima Indians, and national cohorts of diabetes patients. He has brought basic technology directly to the study of human patients, and the combined approach of human physiology, genetics, and basic cell and molecular biology has provided the laboratory with a flexible capability for hypothesis testing relevant to human disease. By studying molecular parameters and differential gene expression in muscle and fat tissue from metabolically characterized individuals, the Garvey laboratory has made important observations regarding the pathogenesis of human insulin resistance. He has been a principle contributor to our understanding of the role of the glucose transport system and glucose transporter proteins in human insulin resistance. The laboratory has also identified a polymorphisms in the uncoupling protein 3 gene as a "thrifty gene" and susceptibility gene for severe obesity in African Americans. He also served as the PI of an NIH-funded Program Project to study markers and mechanisms of diabetes vascular complications in collaboration with two national trial cohorts. Dr. Garvey has directed an independent laboratory since 1987 supported by the National Institutes of Health (NIDDK, NHLBI), the Department of Veterans Affairs, the AHA, JDFI, the ADA, and other agencies. Dr. Garvey also has a track record of community based research and outreach in the context of two initiatives, Project Sugar (a genetics study among Gullah-speaking African Americans) and MUSC/HBCU Partners in Wellness (a program in community health at 6 historically black colleges and universities in SC intended to challenge minority students towards careers in the health professions).

    He has provided service as a member of national research review committees for the Juvenile Diabetes Research Foundation, the American Diabetes Association, the VA Merit Review Program, and the National Institutes of Health. He was a standing member of the Metabolism Study Section at NIH from 1998-2002, and has chaired several ad hoc NIH study sections. Dr. Garvey currently serves on the editorial boards of Diabetes, and has previously served in this capacity for the Journal of Clinical Endocrinology and Metabolism and Diabetes Reviews. He is a member of the American Society for Clinical Investigation, the Association of American Physicians, the Endocrine Society, and the American Diabetes Association, and the North American Association for the Study of Obesity.

    Dr Garvey is the founding PI of the UAB Diabetes Research Center from 2008 to present (P30 DH079626) and a program project funded by the American Heart Association entitled "Intergenerational Transmission of Obesity and Cardiometabolic Disease" from 2017-2020.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Genetic landscape of Gullah African AmericansAmerican Journal of Physical Anthropology.  175:905-919. 2021
    2021 Exercise training and diet-induced weight loss increase markers of hepatic bile acid (BA) synthesis and reduce serum total BA concentrations in obese women 2021
    2020 COVID-19 & obesity: Beyond BMIEndocrine Practice.  26:923-925. 2020
    2020 Erratum: Exercise plasma metabolomics and xenometabolomics in obese, sedentary, insulin-resistant women: Impact of a fitness and weight loss intervention (American Journal of Physiology - Endocrinology and Metabolism (2019) 317 (E999-E1014) DOI: 10.1152/ajpendo.00091.2019) 2020
    2020 Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: The SCALE insulin randomized controlled trialDiabetes Care.  43:1085-1093. 2020
    2020 Consensus statement by the American Association of clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summaryEndocrine Practice.  26:107-139. 2020
    2019 CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES - 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS - EXECUTIVE SUMMARYEndocrine Practice.  25:1346-1359. 2019
    2019 Commentary from the American association of clinical endocrinologists on the U.S. preventive services task force recommandations regarding weight loss interventionsEndocrine Practice.  25:394-395. 2019
    2019 The diagnosis and evaluation of patients with obesityCurrent Opinion in Endocrine and Metabolic Research.  4:50-57. 2019
    2019 Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 executive summaryEndocrine Practice.  25:69-100. 2019
    2019 Exercise plasma metabolomics and xenometabolomics in obese, sedentary, insulin-resistant women: Impact of a fitness and weight loss intervention 2019
    2018 Application of the AACE/ACE advanced framework for the diagnosis of obesity and cardiometabolic disease staging in a general population from 3 regions of Venezuela: The vemsols study resultsEndocrine Practice.  24:6-13. 2018
    2017 To the editor: Author response to Dr. ZhuEndocrine Practice.  23:888. 2017
    2017 Letter to the EditorEndocrine Practice.  23:749-750. 2017
    2016 Patient-centered care of the patient with obesityEndocrine Practice.  22:1-21. 2016
    2016 Effects of liraglutide 3.0 mg on weight and risk factors in hispanic versus non-hipanic populations: Subgroup analysis from scale randomized trialsEndocrine Practice.  22:1277-1287. 2016
    2016 Skeletal muscle TRIB3 mediates glucose toxicity in diabetes and high-fat diet-induced insulin resistanceDiabetes.  65:2380-2391. 2016
    2016 AP2-NR4A3 transgenic mice display reduced serum epinephrine because of increased catecholamine catabolism in adipose tissue 2016
    2016 Do glycemic marker levels vary by race? Differing results from a cross-sectional analysis of individuals with and without diagnosed diabetesBMJ Open Diabetes Research and Care.  4:1-8. 2016
    2016 Ablation of the duodenal mucosa as a strategy for glycemic control in type 2diabetes: Role of nutrient signaling or simple weight lossDiabetes Care.  39:2108-2110. 2016
    2016 Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetesAtherosclerosis.  244:93-100. 2016
    2015 Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of ActionCurrent Obesity Reports.  4:287-302. 2015
    2015 AACE/ACE comprehensive diabetes management algorithm 2015Endocrine Practice.  21:438-447. 2015
    2015 AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARYEndocrine Practice.  21:413-437. 2015
    2015 AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY - CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN - 2015.Endocrine Practice.  21 Suppl 1:1-87. 2015
    2015 AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARYEndocrine Practice.  21:413-437. 2015
    2014 Insulin exerts direct, IGF-1 independent actions in growth plate chondrocytesBone Research.  2. 2014
    2014 Influence of acute hyperlipidemia to adipocyte-derived hormones in lean normotensive and subjects with metabolic syndrome 2014
    2014 KSRP ablation enhances brown fat gene program in white adipose tissue through reduced miR-150 expressionDiabetes.  63:2949-2961. 2014
    2014 Novel effects of Brefeldin A (BFA) in signaling through the insulin receptor (IR) pathway and regulating FoxO1-mediated transcription.Cellular Logistics.  4:e27732. 2014
    2014 Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: A prospective studyAtherosclerosis.  236. 2014
    2013 TRIB3 mediates glucose-induced insulin resistance via a mechanism that requires the hexosamine biosynthetic pathwayDiabetes.  62:4192-4200. 2013
    2013 6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3 2013
    2013 Type 2 diabetes with partial lipodystrophy of the limbs: A new lipodystrophy phenotypeDiabetes Care.  36:2247-2253. 2013
    2013 A complications-based clinical staging of obesity to guide treatment modality and intensity 2013
    2013 Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: Cosponsored by the American association of clinical endocrinologists/the american college of endocrinology and the obesity society: Executive summaryEndocrine Practice.  19:875-887. 2013
    2013 New tools for weight-loss therapy enable a more robust medical model for obesity treatment: Rationale for a complications-centric approachEndocrine Practice.  19:864-874. 2013
    2013 American association of clinical endocrinologists' comprehensive diabetes management algorithm 2013 consensus statementEndocrine Practice.  19:1-48. 2013
    2013 Enhanced adiponectin actions by overexpression of adiponectin receptor 1 in macrophagesAtherosclerosis.  228:124-135. 2013
    2013 AdR1-TG/TALLYHO mice have improved lipid accumulation and insulin sensitivityBiochemical and Biophysical Research Communications.  433:567-572. 2013
    2013 Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: Cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric SurgeryEndocrine Practice.  19:337-372. 2013
    2012 Role of TRIB3 in regulation of insulin sensitivity and nutrient metabolism during short-term fasting and nutrient excess 2012
    2012 Adiponectin-AdipoR1/2-APPL1 signaling axis suppresses human foam cell formation: Differential ability of AdipoR1 and AdipoR2 to regulate inflammatory cytokine responsesAtherosclerosis.  221:66-75. 2012
    2011 Decreased progression to diabetes in subjects with prediabetes after 2 years of treatment with controlled-release phentermine/topiramateDiabetologia.  54:S371-S371. 2011
    2011 Effects of macrophage-specific adiponectin expression on lipid metabolism in vivo 2011
    2010 Colesevelam in Combination with Metformin Significantly Reduces Low-Density Lipoprotein Particle Concentration in Patients with Early Type 2 DiabetesCirculation.  122. 2010
    2010 Deletion of insulin receptor in chondrocytes sensitizes IGF-1 signaling and actionBONE.  47:S446-S446. 2010
    2010 Initial treatment with metformin plus colesevelam provides greater glycaemic control than metformin alone in Hispanic patients with type 2 diabetes mellitusDiabetologia.  53. 2010
    2010 Changes in Insulin Sensitivity in Overweight/Obese Patients Treated with Low-Dose, Controlled-Release Phentermine/Topiramate(PHEN/TPM)Diabetes.  59:A481-A481. 2010
    2010 Effects of Resistance Exercise and Aging on NR4A Protein Levels in Skeletal MuscleDiabetes.  59:A319-A320. 2010
    2010 The Safety and Tolerability of Metformin plus Colesevelam in Drug-Naive Patients with Early Type 2 Diabetes MellitusDiabetes.  59:A173-A173. 2010
    2010 Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: Role in glucose-induced insulin resistance 2010
    2010 A diabetes-specific enteral formula improves glycemic variability in patients with type 2 diabetes.Diabetes Technology and Therapeutics.  12:419-425. 2010
    2010 Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study.Endocrine Practice.  16:617-628. 2010
    2010 Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes.Endocrine Practice.  16:629-640. 2010
    2009 Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistanceDiabetes.  58:2498-2505. 2009
    2009 A qualitative assessment of educational opportunities for primary care providers in type 2 diabetes careDiabetes Spectrum.  22:248-253. 2009
    2009 H. pylori-induced higher C-reactive protein in obese African AmericansArtery Research.  3:39-42. 2009
    2009 Adiponectin reduces lipid accumulation in macrophage foam cellsAtherosclerosis.  202:152-161. 2009
    2009 NUTRITION AND CONTROL OF DIABETES IN HOSPITALIZED PATIENTS 2009
    2008 Genome-wide linkage scan in Gullah-speaking African American families with Type 2 diabetes: The Sea Islands Genetic African American Registry (Project SuGAR)Diabetes.  57:A321-A321. 2008
    2008 Metabolic syndrome traits and endothelial dysfunction: Role of ethnicityDiabetes.  57:A620-A620. 2008
    2008 Osteocalcin is not just for bones: Effects on adipocytes and role in human metabolismDiabetes.  57:A29-A29. 2008
    2008 Diagnosis and management of prediabetes in the continuum of hyperglycemia - When do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical EndocrinologistsEndocrine Practice.  14:933-946. 2008
    2007 Adiponectin and the metabolic syndrome: Mechanisms mediating risk for metabolic and cardiovascular diseaseCurrent Opinion in Lipidology.  18:263-270. 2007
    2007 Ethnic differences in adiponectin multimer distribution and relationships with metabolic syndrome traitsDiabetes.  56:A361-A361. 2007
    2007 Fat depots and adipokines in morbidly obese individualsDiabetes.  56:A464-A464. 2007
    2007 Pioglitazone therapy restores the coupling of electron transport to ATP synthesis in skeletal muscle of obese zucker ratsDiabetes.  56:A85-A86. 2007
    2007 The effect of insulin on expression of genes and biochemical pathways in human skeletal muscleEndocrine.  31:5-17. 2007
    2007 The effect of insulin on expression of genes and biochemical pathways in human skeletal muscle (Endocrine (2007) 31, 1 (5-17) DOI: 10.1007/s12020-007- 0007-x)Endocrine.  32:356. 2007
    2006 Polymorphism in the transcription factor 7-Like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic womenDiabetes.  55:3630-3634. 2006
    2006 Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophagesAtherosclerosis.  188:102-111. 2006
    2006 A role for C/EBP-delta in mitochondrial dysfunction and insulin resistance in skeletal muscleDiabetes.  55:A304-A304. 2006
    2006 Resistin autoregulates inflammatory cytokine production and induces insulin resistance in adipocytesDiabetes.  55:A310-A310. 2006
    2006 Molecular characterization of human melanocortin-3 receptor ligand-receptor interactionBiochemistry.  45:1128-1137. 2006
    2006 Adiponectin multimeric complexes and the metabolic syndrome trait clusterDiabetes.  55:249-259. 2006
    2005 Modified lipoprotein-immune complexes and progression of internal carotid intima-media thickness in type 1 diabetesCirculation.  112:U848-U849. 2005
    2005 Mitochondrial DNA genetic diversity among four ethnic groups in Sierra LeoneAmerican Journal of Physical Anthropology.  128:156-163. 2005
    2005 Mitochondrial DNA (mtDNA) haplotypes reveal maternal population genetic affinities of Sea Island Gullah-speaking African AmericansAmerican Journal of Physical Anthropology.  127:427-438. 2005
    2005 Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophagesDiabetes.  54:A188-A188. 2005
    2005 Proteomics analysis of skeletal muscle mitochondria in type 2 diabetes reveals altered concentrations and oxidation of respiratory chain proteinsDiabetes.  54:A58-A59. 2005
    2004 Associations of adiponectin with retinopathy in the DCCT/EDIC cohort: Influence of insulin resistanceDiabetes.  53:A254-A254. 2004
    2004 Estimation of resting energy expenditure considering effects of race and diabetes statusDiabetes Care.  27:1405-1411. 2004
    2004 Overexpression of adiponectin but not resistin enhances adipocyte differentiation and insulin sensitivityDiabetes.  53:A79-A79. 2004
    2004 Critical Evaluation of Adult Treatment Panel III Criteria in Identifying Insulin Resistance with DyslipidemiaDiabetes Care.  27:978-983. 2004
    2004 Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: A role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formationBlood Cells, Molecules and Diseases.  32:182-190. 2004
    2003 Lipoprotein abnormalities in type 1 diabetes 2003
    2003 Serum lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications cohort: Associations with gender and glycemiaDiabetes Care.  26:810-818. 2003
    2002 The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophagesAtherosclerosis.  165:259-269. 2002
    2002 Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetesDiabetes Research and Clinical Practice.  58:87-96. 2002
    2002 Troglitazone antagonizes metabolic effects of glucocorticoids in humans: Effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptinDiabetes.  51:2895-2902. 2002
    2002 Hepatic lipase gene polymorphism is a major determinant of HDL level and HDL size in men with type 1 diabetes in the DCCT/EDICDiabetes.  51:A20-A20. 2002
    2001 A role for the Agouti-Related Protein promoter in obesity and type 2 diabetesBiochemical and Biophysical Research Communications.  287:568-573. 2001
    2001 Postprandial glucose and insulin responses to dextrin-containing medical nutritional bars in persons with type 2 diabetes mellitusDiabetes.  50:A366-A366. 2001
    2001 Ancestral proportions and admixture dynamics in geographically defined African Americans living in South CarolinaAmerican Journal of Physical Anthropology.  114:18-29. 2001
    2000 Short-term impact of a church-based approach to lifestyle change on cardiovascular risk in African AmericansEthnicity and Disease.  10:17-23. 2000
    2000 Nuclear magnetic resonance (NMR)-determined lipoprotein subclass profile in the DCCT/EDIC cohort: Associations with retinopathy and nephropathyDiabetes.  49:A269-A269. 2000
    2000 Nuclear magnetic resonance (NMR)-determined lipoprotein subclass profile in the DCCT/EDIC cohort: Effects of gender, HbAlc, and DCCT randomization group.Diabetes.  49:A267-A267. 2000
    2000 Troglitazone is an effective therapeutic agent in patients with steroid-induced diabetesDiabetes.  49:A129-A129. 2000
    2000 High-resolution admixture map of African Americans living in South Carolina.American Journal of Physical Anthropology.  245-246. 2000
    1999 Aberrant DNA sequence pattern caused by a heterozygosity 1999
    1999 Low birth weight is associated with reduced expression of GLUT4 and carnitine palmitoyltransferase-1 in adult skeletal muscleDiabetes.  48:A274-A275. 1999
    1999 Sickle cell haplotypes of the African American "Gullah" of the South Carolina Sea Islands.American Journal of Physical Anthropology.  233-234. 1999
    1999 Troglitazone prevents glucocorticoid-induced insulin resistance in humansDiabetes.  48:A75-A75. 1999
    1998 Insulin resistance and defective glucose-insulin coupling in ketosis-prone type 2 diabetes of African-American youthDiabetes.  47:A306-A306. 1998
    1998 The role of uncoupling proteins in metabolic fuel partitioning and human obesityDiabetes.  47:A13-A13. 1998
    1998 Clinical implications of the insulin resistance syndromeClinical Cornerstone.  1:13-26. 1998
    1997 Muscle rad expression and human metabolism: Potential role of the novel ras-related GTPase in energy expenditure and body compositionDiabetes.  46:444-450. 1997
    1996 Correlation of leptin and body fat in obese, lean, and lipodystrophic humans.Diabetes.  45:1229-1229. 1996
    1996 Fat and muscle tissue express a common abnormality in translocation/trafficking of GLUT4/vp165 containing vesicles in NIDDM.Diabetes.  45:573-573. 1996
    1995 GLUCOSAMINE (GLMN) INDUCES INSULIN-RESISTANCE (IR) IN-VIVO BY AFFECTING GLUT 4 TRANSLOCATION IN SKELETAL-MUSCLE - IMPLICATIONS FOR GLUCOSE TOXICITYDiabetes.  44:A15-A15. 1995
    1994 MUSCLE GLUT 4 EXPRESSION IS A FAMILIAL TRAIT AND DETERMINES INSULIN SENSITIVITY IN HUMANS INDEPENDENT OF OBESITYDiabetes.  43:A69-A69. 1994
    1994 MOLECULAR ADAPTATIONS OF GLUT1 AND GLUT2 IN RENAL PROXIMAL TUBULES OF DIABETIC RATSAmerican Journal of Physiology.  266:F283-F290. 1994
    1994 Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats.American Journal of Physiology.  266:F283-F290. 1994
    1994 Glucose transporter proteins and insulin sensitivity in humans.Brazilian Journal of Medical and Biological Research.  27:933-939. 1994
    1994 Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic ratsAmerican Journal of Physiology.  266. 1994
    1993 EFFECTS OF DIABETES ON MYOCARDIAL GLUCOSE-TRANSPORT SYSTEM IN RATS - IMPLICATIONS FOR DIABETIC CARDIOMYOPATHYAmerican Journal of Physiology.  264:H837-H844. 1993
    1993 Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy.American Journal of Physiology.  264:H837-H844. 1993
    1993 1 Cellular insulin action and insulin resistance 1993
    1993 Effects of diabetes on myocardial glucose transport system in rats: Implications for diabetic cardiomyopathyAmerican Journal of Physiology.  264. 1993
    1993 Potential role for insulin and cycloheximide in regulating the intrinsic activity of glucose transporters in isolated rat adipocytesEndocrinology.  133:2943-2950. 1993
    1992 MECHANISMS OF ENHANCED INSULIN ACTION IN ENDURANCE-TRAINED ATHLETESClinical research.  40:A733-A733. 1992
    1992 GLUCOSE TRANSPORTERS OF RAT PROXIMAL TUBULE - DIFFERENTIAL EXPRESSION AND SUBCELLULAR-DISTRIBUTIONAmerican Journal of Physiology.  262:F807-F812. 1992
    1992 Glucose transporters of rat proximal tubule: differential expression and subcellular distribution.American Journal of Physiology.  262:F807-F812. 1992
    1992 DIABETES DEPRESSES THE RAT CARDIAC NA+/CA2+ EXCHANGERClinical research.  40:A257-A257. 1992
    1992 Glucose transporters of rat proximal tubule: Differential expression and subcellular distributionAmerican Journal of Physiology.  262. 1992
    1991 ADAPTATIONS OF THE RAT RENAL PROXIMAL TUBULE TO UNCONTROLLED DIABETESClinical research.  39:A307-A307. 1991
    1991 REGULATION OF TISSUE GLUT4 CONTENT VARIES AS A FUNCTION OF SKELETAL-MUSCLE GROUP AND CANNOT TOTALLY EXPLAIN INSULIN RESISTANCE IN DIABETIC RATSClinical research.  39:A354-A354. 1991
    1988 Correlation of in vivo and in vitro actions of insulin in obesity and noninsulin-dependent diabetes mellitus: Role of the glucose transport system 1988
    1986 Insulin induces progressive insulin resistance in cultured rat adipocytes: Sequential effects at receptor and multiple postreceptor sitesDiabetes.  35:258-267. 1986

    Book

    Year Title Altmetric
    2018 Preface 2018

    Chapter

    Year Title Altmetric
    2018 Clinical definition of overweight and obesity.  121-143. 2018
    2010 Insulin Action.  104-125. 2010
    2006 16 - Metabolic Syndrome.  357-370. 2006

    Research Overview

  • The Garvey laboratory is interested in the molecular, metabolic, and genetic basis of type 2 diabetes mellitus, insulin resistance, and obesity. Studies involve cellular and molecular biology of cell and animal models, metabolic investigations of human subjects on a clinical research ward, and genetic epidemiology. The combined approach of human physiology, genetics, and basic cell and molecular biology provides the laboratory with a flexible and powerful capability for hypothesis testing relevant to human disease. Principal research activities include:

    Role of GLUT 4 glucose transporters and the glucose transport system in insulin resistance. This work utilizes cultured cell, animal models, and humans (in vivo metabolic studies and ex vivo studies of tissues) as model systems, and tests hypotheses relating to abnormalities in GLUT gene expression and cellular trafficking of GLUT4-containing vesicles.

    Molecular Mechanisms of Human Insulin Resistance. The laboratory systematically identifies differential gene expression in muscle and fat from insulin sensitive, insulin resistant, and Type 2 Diabetic patients using cDNA microarrays and proteomics. The contribution of selected novel genes/proteins in cell biology and metabolism is investigated using a variety of methodologies including gene hyperexpression/knock-out in cultured cells and mice.

    Molecular and Metabolic Defects Impairing Lipid Oxidation in Insulin Resistance. These studies feature application of NMR and metabolomic approaches, with a special focus on mitochondrial function, to explain defective lipid oxidation and lipid accumulation in skeletal muscle.

    Interaction between Environment and Genes in the Pathogenesis of Diabetes and Obesity and Related Metabolic Subphenotypes. These studies examine the contribution of specific gene polymorphisms (for example UCP3) to clinical and metabolic traits in relationship to environmental parameters such as diet and physical activity. Study groups include Gullah speaking African Americans and families with adolescent sib pairs discordant for obesity and/or Type 2 Diabetes.

    Pathophysiology and Clinical Diagnoses of the Insulin Resistance (or Metabolic) Syndrome. These studies include the impact of race and racial genetic admixture of the Insulin Resistance Syndrome trait cluster.

    Markers and Mechanisms of Vascular Disease in Diabetes. These studies involve secreted factors from adipocytes and gene polymorphisms, and collaborations with the DCCT/EDIC Study Group (i.e., the national cohort of DCCT/EDIC patients with Type 1 Diabetes) and the VA Diabetes Study (i.e., a VA cooperative study in Type 2 Diabetic patients).

    Dr. Garvey’s career has been distinguished by a second impactful sphere of activity. He has developed an intense interest in our understanding of obesity as a disease, and in advancing medical models to improve the care of patients with obesity. Dr. Garvey was the chief architect of the Complications-Centric Model for Care of the Overweight/Obese Patient. Much of his work in this area has occurred as a member in the American Association of Clinical Endocrinologists (AACE). Garvey was a leading contributor and author in the AACE Position Statement designating Obesity as a disease; the AACE proposition voted by the AMA House of Delegates affirming Obesity as a disease in 2013; the obesity treatment algorithm in the AACE Comprehensive Diabetes Management Algorithms; and lead author on the evidence-based AACE obesity management guidelines; and co-author of the new medical diagnostic term for obesity – Adiposity-Based Chronic Disease. This obesity treatment algorithm emphasizes the use of weight loss therapy to treat obesity-related complications as the primary goal of treatment, as opposed to reductions in BMI per se. Further, Dr. Garvey developed Cardiometabolic Disease Staging that allows clinicians to quantitatively assign risk for Type 2 Diabetes and cardiovascular disease mortality, when deciding upon the treatment modality and intensity of weight loss therapy for their patients, within the context of a complications-centric medical approach. This work is widely applicable and relevant to policy-making regarding the prevention of diabetes. Thus, Dr. Garvey is a national leader in the development of medical models for the management of obesity and diabetes prevention.
  • Principal Investigator On

  • A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus  awarded by Duke University
  • Continuation of Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)  awarded by George Washington University
  • Emotional Distress in a Comparative Effectiveness Trial of Diabetes Treatments  awarded by George Washington University
  • Genetic Contributors to Diabetes and Dyslipidemia in African Americans  awarded by University of Virginia
  • Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study  awarded by George Washington University
  • Identification of Muscle-Specific Biomarkers of Fatty Acid Beta-Oxidation  awarded by Agricultural Research Service/Department of Agriculture
  • Intergenerational Transmission of Obesity  awarded by American Heart Association
  • Intergenerational Transmission of Obesity - Intergenerational Transmission of Obesity in Mouse Models of in Utero Stress  awarded by American Heart Association
  • Intergenerational Transmission of Obesity - UAB Strategically Focused Obesity Center (SFOC)  awarded by American Heart Association
  • Mechanisms of Human Insulin Resistance  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • NR4A Orphan Receptors and Insulin Resistance  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Obesity Health Disparities Research Center (OHDRC) - Administrative Core  awarded by NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES/NIH/DHHS
  • Obesity Training Program (T32 DK 062710) - DiaComp Coordinating and Bioinformatics Unit  awarded by AUGUSTA UNIVERSITY - NEW
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by Genzyme Corporation
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by ABBOTT NUTRITION
  • Private Grant  awarded by Nestle
  • Private Grant  awarded by WEIGHT WATCHERS INTERNATIONAL, INC.
  • Private Grant  awarded by VIVUS, INC.
  • Private Grant  awarded by EISAI, INC.
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by LEXICON PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by ELCELYX THERAPEUTICS, INC.
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by LILLY USA, LLC
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy  awarded by Duke University
  • UAB Clinical Nutrition Research Unit - Core B (Genetics)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Diabetes Research Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Diabetes Research Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Diabetes Research Center - Administrative Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Diabetes Research Center - Administrative Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Diabetes Research and Training Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Diabetes Research and Training Center - Administrative Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Obesity Training Program  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Obesity Training Program  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Investigator On

  • A Sleep and Media Intervention to Improve Adolescents Weight and Risk of Type 2 Diabetes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Adapting MultiPLe Behavior Interventions that eFfectively Improve (AMPLIFI) Cancer Survivor Health  awarded by National Cancer Institute/NIH/DHHS
  • Adapting MultiPLe Behavior Interventions that eFfectively Improve (AMPLIFI) Cancer Survivor Health - Administrative Core  awarded by National Cancer Institute/NIH/DHHS
  • Comparing High and Normal Protein Diets for the Dietary Remission of Type 2 Diabetes  awarded by National Cattlemen's Beef Association
  • Depletion of Pancreatic Lipid Improves Beta-Cell Function in Early Type 2 Diabetes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Effect Of Time-Restricted Feeding On 24-Hour Glycemic Control, Blood Pressure, And Cardiovascular Disease Risk Factors In Adults With Prediabetes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Evaluating Community Health Advisors on Diabetes Outcomes in Rural Alabama (ENCOURAGE)  awarded by American Academy of Family Physicians Foundation
  • Identification for Predictors of Future Diabetes - Impacts of Stress and Depression  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Integrative -omics Study of Postprandial Lipoprotein Phenotypes  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Intergenerational Transmission of Obesity  awarded by American Heart Association
  • Kidney Undergraduate Research Experience (KURE)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Novel Actions of Metformin to Augment Resistance Training Adaptations in Older Adults  awarded by UNIVERSITY OF KENTUCKY (RESEARCH FOUNDATION)
  • Obesity Health Disparities Research Center (OHDRC)  awarded by NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES/NIH/DHHS
  • Obesity Risk in African American Women is Determined by a Diet-by-Phenotype Interaction  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • PRedoctoral Interdisciplinary Training in Renal Physiology and MEdIcIne (PRIME)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Race - Adiposity Interactions Regulate Mechanisms Determining Insulin Sensitivity  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Thrombocytopoiesis in Diabetes: Role of Damage Associated Molecular Patterns  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Trace Mineral Levels, Metabolomics, and Diabetes Risk  awarded by Indiana University
  • Trace Mineral Levels, Metabolomics, and Diabetes Risk  awarded by Columbia University
  • Training Program in Cardiovascular Pathophysiology  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • UAB Diabetes Research Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Diabetes Research Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Nutrition Obesity Research Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Nutrition Obesity Research Center (NORC)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Nutrition Obesity Research Center (NORC) - Administrative Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Nutrition Obesity Research Center - Core A - Administrative Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB Obesity Training Program  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • UAB STEP-UP: Promoting Diversity Through Mentored Research Experiences (UAB STEP-UP)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Using Early Time-Restricted Feeding and Timed Light Therapy to Improve Glycemic Control in Adults with Type 2 Diabetes  awarded by DOD - Department of Defense
  • Teaching Activities

  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2021) 2021
  • NTR798 - Doc Level Non-Dissertation Res (Fall Term 2020) 2020
  • NTR798 - Doc Level Non-Dissertation Res (Summer Term 2020) 2020
  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2020) 2020
  • NTR798 - Doc Level Non-Dissertation Res (Fall Term 2019) 2019
  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2019) 2019
  • NTR699 - Master's Level Thesis Research (Fall Term 2018) 2018
  • NTR799 - Doc Lev Dissertation Research (Summer Term 2018) 2018
  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2018) 2018
  • NTR799 - Doc Lev Dissertation Research (Spring Term 2018) 2018
  • NTR798 - Doc Level Non-Dissertation Res (Fall Term 2017) 2017
  • NTR798 - Doc Level Non-Dissertation Res (Summer Term 2017) 2017
  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2017) 2017
  • NTR798 - Doc Level Non-Dissertation Res (Fall Term 2016) 2016
  • NTR798 - Doc Level Non-Dissertation Res (Summer Term 2016) 2016
  • NTR799 - Doc Lev Dissertation Research (Summer Term 2016) 2016
  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2016) 2016
  • NTR799 - Doc Lev Dissertation Research (Spring Term 2016) 2016
  • NTR798 - Doc Level Non-Dissertation Res (Fall Term 2015) 2015
  • NTR798 - Doc Level Non-Dissertation Res (Summer Term 2015) 2015
  • NTR799 - Doc Lev Dissertation Research (Summer Term 2015) 2015
  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2015) 2015
  • NTR799 - Doc Lev Dissertation Research (Spring Term 2015) 2015
  • NTR798 - Doc Level Non-Dissertation Res (Fall Term 2014) 2014
  • NTR799 - Doc Lev Dissertation Research (Fall Term 2014) 2014
  • NTR799 - Doc Lev Dissertation Research (Summer Term 2014) 2014
  • NTR699 - Master's Level Thesis Research (Spring Term 2014) 2014
  • NTR799 - Doc Lev Dissertation Research (Spring Term 2014) 2014
  • NTR798 - Doc Level Non-Dissertation Res (Fall Term 2013) 2013
  • NTR799 - Doc Lev Dissertation Research (Fall Term 2013) 2013
  • NTR699 - Master's Level Thesis Research (Summer Term 2013) 2013
  • NTR798 - Doc Level Non-Dissertation Res (Summer Term 2013) 2013
  • NTR699 - Master's Level Thesis Research (Spring Term 2013) 2013
  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2013) 2013
  • NTR799 - Doc Lev Dissertation Research (Spring Term 2013) 2013
  • NTR798 - Doc Level Non-Dissertation Res (Fall Term 2012) 2012
  • NTR799 - Doc Lev Dissertation Research (Fall Term 2012) 2012
  • NTR798 - Doc Level Non-Dissertation Res (Summer Term 2012) 2012
  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2012) 2012
  • NTR798 - Doc Level Non-Dissertation Res (Fall Term 2011) 2011
  • NTR799 - Doc Lev Dissertation Research (Fall Term 2011) 2011
  • NTR798 - Doc Level Non-Dissertation Res (Summer Term 2011) 2011
  • NTR799 - Doc Lev Dissertation Research (Summer Term 2011) 2011
  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2011) 2011
  • NTR799 - Doc Lev Dissertation Research (Spring Term 2011) 2011
  • NTR798 - Doc Level Non-Dissertation Res (Fall Term 2010) 2010
  • NTR799 - Doc Lev Dissertation Research (Fall Term 2010) 2010
  • NTR798 - Doc Level Non-Dissertation Res (Summer Term 2010) 2010
  • NTR799 - Doc Lev Dissertation Research (Summer Term 2010) 2010
  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2010) 2010
  • NTR799 - Doc Lev Dissertation Research (Spring Term 2010) 2010
  • NTR799 - Doc Lev Dissertation Research (Fall Term 2009) 2009
  • NTR798 - Doc Level Non-Dissertation Res (Summer Term 2009) 2009
  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2009) 2009
  • NTR699 - Master's Level Thesis Research (Fall Term 2008) 2008
  • NTR798 - Doc Level Non-Dissertation Res (Fall Term 2008) 2008
  • NTR798 - Doc Level Non-Dissertation Res (Summer Term 2008) 2008
  • NTR798 - Doc Level Non-Dissertation Res (Spring Term 2008) 2008
  • NTR798 - Doc Level Non-Dissertation Res (Fall Term 2007) 2007
  • Education And Training

  • Barnes Hospital, Internship
  • Barnes Hospital, Residency
  • University of California San Diego Medical Center, Postdoctoral Fellowship
  • University of Colorado Health Sciences Center, Postdoctoral Fellowship
  • Doctor of Medicine, Saint Louis University 1978
  • Bachelor of Arts in Biology, Washington University/St. Louis 1974
  • Full Name

  • W. Timothy Garvey